JOURNAL ARTICLE
MULTICENTER STUDY

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study

Richard Moreau, Francois Durand, Thierry Poynard, Christian Duhamel, Jean-Paul Cervoni, Philippe Ichaï, Armand Abergel, Chantal Halimi, Mathieu Pauwels, Jean-Pierre Bronowicki, Emile Giostra, Cathy Fleurot, Danielle Gurnot, Olivier Nouel, Philippe Renard, Michel Rivoal, Pierre Blanc, Dimitri Coumaros, Sylvie Ducloux, Stephane Levy, Alexandre Pariente, Jean-Marc Perarnau, Jean Roche, Myriam Scribe-Outtas, Dominique Valla, Brigitte Bernard, Didier Samuel, Joël Butel, Antoine Hadengue, Andrzej Platek, Didier Lebrec, Jean-Francois Cadranel
Gastroenterology 2002, 122 (4): 923-30
11910344

BACKGROUND & AIMS: Type 1 hepatorenal syndrome (HRS) is a severe complication of cirrhosis associated with a short median survival time (<2 weeks). Although the administration of terlipressin improves renal function, its effect on survival is unknown. This study investigated predictive factors of survival in patients with type 1 HRS treated with terlipressin.

METHODS: Ninety-nine patients with type 1 HRS treated with terlipressin in 24 centers were retrospectively studied. Terlipressin-induced improved renal function was defined as a decrease in serum creatinine value to <130 micromol/L or a decrease of at least 20% at the end of treatment.

RESULTS: At inclusion, the Child-Pugh score was 11.8 +/- 1.6 (mean +/- SD). Terlipressin (3.2 +/- 1.3 mg/day) was administered for 11 +/- 12 days. Renal function improved in 58% of patients (serum creatinine decreased by 46% +/- 17% from 272 +/- 114 micromol/L). Median survival time was 21 days. Survival rate was 40% at 1 month. Multivariate analysis showed that improved renal function and Child-Pugh score < or =11 at inclusion were independent predictive factors of survival (P < 0.0001 and 0.02, respectively). Thirteen patients underwent liver transplantation (92 +/- 95 days after HRS onset), 10 of whom had received terlipressin and had had improved renal function.

CONCLUSIONS: This retrospective uncontrolled study shows that in patients with type 1 HRS, terlipressin-induced improved renal function is associated with an increase in survival. Thus, a randomized trial investigating the effect of terlipressin on survival in patients with type 1 HRS should be performed.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Trending Papers

Remove bar
Read by QxMD icon Read
11910344
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"